Stanley Jordan, MD
Nephrology · West Hollywood, CANPI 1669432167
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.3%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by CSL Behring at 26.9% of the total. Reporting peaked in 2023 at $59,607 and has fallen 60.3% since, to $23,646 in 2025. Among nephrology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 134 payments — averaging $1575.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$57K
- Regeneron$47K
- Astellas Pharma Inc$37K
- Argenx US, Inc.$31K
- Mallinckrodt Hospital Products Inc.$15K
- Apellis Pharmaceuticals, Inc.$9K
- plus $15K from 11 others
Across 278 payments — averaging $6610.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$1M
- Regeneron$596K
- Sanofi US Services Inc.$94K
- Astellas Pharma Global Development$53K
- Roche Products Limited$18K
- Novartis$17K
- plus $31K from 3 others
What the payments were for
- Consulting fees$118,90456%
- Speaking & faculty fees$22,54711%
- Travel & lodging$65,34431%
- Food & beverage$4,3542%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 40 | $56,902 |
| Regeneron | 38 | $47,334 |
| Astellas Pharma Inc | 10 | $36,903 |
| Argenx US, Inc. | 10 | $30,769 |
| Mallinckrodt Hospital Products Inc. | 6 | $15,259 |
| Apellis Pharmaceuticals, Inc. | 6 | $8,776 |
| Sanofi-aventis U.S. LLC | 8 | $6,709 |
| Vertex | 1 | $3,575 |
| Pfizer | 1 | $2,750 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $1,252 |
| E.r. Squibb & Sons, L.L.C. | 4 | $322 |
| Veloxis Pharmaceuticals, Inc. | 3 | $189 |
| Sanofi | 1 | $150 |
| Vifor Pharma, Inc. | 1 | $106 |
| Biogen | 1 | $91 |
| Amgen | 2 | $42 |
| AstraZeneca | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TACROLIMUS$36,865
- VYVGART$14,400
- UVADEX$13,750
- VYVGART HYTRULO$3,709
- Empaveli$3,304
- ATGAM$2,750
- CELLEX$1,509
- NULOJIX$298
- THYMOGLOBULIN$269
- Envarsus$140
- Berinert$118
- Veltassa$106
How this compares
$211,150 in reported general payments places this provider in the 95th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 24 | $286,748 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 13 | $55,479 |
| NulojixBelatacept | 27 | $41,181 |
| Mycophenolic AcidMycophenolate Sodium | 25 | $3,866 |
| Mycophenolate Mofetil | 68 | $2,621 |
| Tacrolimus | 36 | $2,207 |
| ValacyclovirValacyclovir Hcl | 21 | $1,736 |
| Fluconazole | 24 | $678 |
| Prednisone | 158 | $579 |
| Calcitriol | 19 | $318 |
| Methylprednisolone Sodium SuccMethylprednisolone Sod Succ | 14 | $99 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $44 |
| Levofloxacin | 12 | $31 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringPrivigen | $56,902 | $286,74824 claims |
| E.r. Squibb & Sons, L.L.C.Nulojix | $322 | $41,18127 claims |
| Astellas Pharma IncTacrolimus | $36,903 | $2,20736 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,341 nephrology providers in California.
Other nephrology in West Hollywood
- Mrinalini SarkarWest Hollywood$87K
- Anjay RastogiLos Angeles$2.2M
- Glenn ChertowStanford$2M
- Luis AlvarezPalo Alto$1.8M
- Jose MorfinSacramento$1M
- Rodolfo BatarseRancho Mirage$910K
- Vandana MathurWoodside$769K
- Yasir QaziOrange$618K
- Rafael VillicanaLoma Linda$610K
- Sunil PatelApple Valley$509K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.